.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Zydus Lifesciences recently announced the launch of AI glucose monitors in India. These next-generation Continuous Glucose Monitoring (CGM) devices, Diasens and GlucoLive, aim to transform modern diabetes management. By integrating artificial intelligence, Zydus provides a more connected care ecosystem for patients and clinicians alike. Consequently, this technology bridge improves real-time clinical decision-making.
The new CGM systems stream glucose readings to smartphones every three minutes. Furthermore, this ensures an uninterrupted capture of data, even during the night or in emergencies. The integrated AI layer identifies trends and flags hypoglycemic or hyperglycemic episodes immediately. Additionally, the system links these fluctuations to specific food intake and physical activities. Therefore, clinicians can offer more precise, personalized advice to their patients based on comprehensive glycaemic data. Moreover, the automatic streaming eliminates the need for manual logging by the patient.
The technology functions through the TatvaCare GoodFlip application. This app generates actionable insights from complex data sets. Because the app shares data in real-time, caregivers and doctors can intervene more quickly. Such advancements simplify the monitoring process for those living with chronic conditions. Moreover, the closed-loop ecosystem ensures that no critical reading goes unnoticed. This launch strengthens the companion diagnostics portfolio for Zydus in the Indian market.
Q1: How often do the Diasens and GlucoLive devices update glucose readings?
The devices automatically stream glucose readings to the patient’s smartphone every three minutes, ensuring continuous and real-time monitoring.
Q2: What is the primary role of the AI layer in these CGM devices?
The AI layer analyzes data trends to flag hypo- and hyperglycaemic episodes while linking fluctuations to the patient's diet and activity levels.
Q3: Which app is used to view the data from these Zydus AI glucose monitors?
Patients use the TatvaCare GoodFlip app, which provides AI-driven analytics and connects them with clinicians and caregivers.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Zydus Lifesciences introduces AI-powered Diasens and GlucoLive CGM devices in India for real-time glucose tracking and advanced diabetes management insights...
4 months ago
A Parliamentary panel recommendation to benchmark private hospital room tariffs against three-star hotels has triggered debate on capital viability, infrastructure growth, and clinical autonomy. Read about the implications for hospital expansion, cashless insurance claims, and physician decision-making.
Today
A multicenter MPOG database study of 289,047 cesarean delivery cases analyzed adherence to obstetric anesthesia best practices. General anesthesia avoidance reached 97.0%, while post-spinal vasopressor infusions (55.4%) and hypothermia prevention (56.7%) showed the lowest compliance, highlighting key targets.
Yesterday
A comprehensive meta-analysis shows digital health technologies significantly improve 6-minute walk distance and peak oxygen uptake in chronic heart failure patients, highlighting the clinical promise of structured remote cardiac rehabilitation.
Today
Recent research assesses an automated pipeline for CT-based vertebral finite element analysis, revealing how boundary condition components—especially load-point assignment—impact fracture-load accuracy in spinal biomechanics.
Today
A comprehensive analysis of continuous glucose monitoring systems under European Medical Device Regulation 2017/745, examining conformity assessment challenges, Notified Body backlogs, EUDAMED rollout delays, and the critical need for transparent post-market surveillance.
Today
